These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38731256)

  • 1. Understanding Patterns of Adherence to Antifibrotic Treatment in Idiopathic Pulmonary Fibrosis: Insights from an Italian Prospective Cohort Study.
    Iommi M; Gonnelli F; Bonifazi M; Faragalli A; Mei F; Pompili M; Carle F; Gesuita R
    J Clin Med; 2024 May; 13(9):. PubMed ID: 38731256
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
    Takehara K; Koga Y; Hachisu Y; Utsugi M; Sawada Y; Saito Y; Yoshimi S; Yatomi M; Shin Y; Wakamatsu I; Umetsu K; Kouno S; Nakagawa J; Sunaga N; Maeno T; Hisada T
    Cells; 2022 Jan; 11(1):. PubMed ID: 35011705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis.
    Porse S; Hoyer N; Shaker SB
    Respir Med; 2022; 204():107015. PubMed ID: 36347111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries.
    Maher TM; Molina-Molina M; Russell AM; Bonella F; Jouneau S; Ripamonti E; Axmann J; Vancheri C
    BMC Pulm Med; 2017 Sep; 17(1):124. PubMed ID: 28915874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis and Survival in Idiopathic Pulmonary Fibrosis in the Era of Antifibrotic Therapy in Italy: Evidence from a Longitudinal Population Study Based on Healthcare Utilization Databases.
    Iommi M; Faragalli A; Bonifazi M; Mei F; Latini LL; Pompili M; Carle F; Gesuita R
    Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
    Cilli A; Uzer F; Sevinç C; Coşkun F; Ursavaş A; Öner Ş; Kose F
    Pulm Pharmacol Ther; 2021 Dec; 71():102099. PubMed ID: 34793978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.
    Kaul B; Lee JS; Petersen LA; McCulloch C; Rosas IO; Bandi VD; Zhang N; DeDent AM; Collard HR; Whooley MA
    Chest; 2023 Aug; 164(2):441-449. PubMed ID: 36801465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study.
    Zhao R; Xie B; Wang X; Zhang X; Ren Y; Wang C; Dai H
    Pulm Pharmacol Ther; 2024 Mar; 84():102287. PubMed ID: 38242314
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Doubkova M; Kriegova E; Littnerova S; Schneiderova P; Sterclova M; Bartos V; Plackova M; Zurkova M; Bittenglova R; Lostaková V; Siskova L; Lisa P; Suldova H; Doubek M; Psikalova J; Snizek T; Musilova P; Vasakova M
    Ther Adv Respir Dis; 2021; 15():17534666211042529. PubMed ID: 34515605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
    Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survival analysis of idiopathic pulmonary fibrosis in the context of antifibrotic therapy in Saudi Arabia.
    Khan MA; Ghamdi BA; Alhamadi M; Rajendram R; Alyami S; Al-Gamedi M; Al-Harbi A; Al-Jahdali H
    Ann Thorac Med; 2023; 18(2):79-85. PubMed ID: 37323372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Real-World Prognosis in Idiopathic Pulmonary Fibrosis: A Special Reference to the Role of Antifibrotic Agents for the Elderly.
    Honda K; Saraya T; Ishii H
    J Clin Med; 2023 May; 12(10):. PubMed ID: 37240670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NICEFIT-A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan.
    Cheng SL; Sheu CC; Chian CF; Hsu JY; Kao KC; Hang LW; Lin CH; Fang WF; Wang HC; Perng DW
    Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients.
    Nili M; Epstein AJ; Nunag D; Olson A; Borah B
    BMC Pulm Med; 2023 Jun; 23(1):230. PubMed ID: 37370093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.